Maha Katabi is a General Partner of Sofinnova Investments. She is an experienced investor with over two decades of managing public and private biotech companies through bull and bear markets. She is currently a board member of ARTBIO, Marea, Quanta, Star, and Vera (VERA). Most recently Maha was a board member of Aiolos (acquired by GSK) and RayzeBio (RYZB: acquired by BMS), in addition to Amplyx (acquired by Pfizer), Gyroscope (acquired by Novartis) and Northsea. Prior to joining Sofinnova in 2019, Maha was a Partner at Sectoral Asset Management. There, she formed and led a dedicated team to manage investments in private companies and was a Portfolio Manager for a family of funds investing in small cap healthcare companies. Maha co-invested with Sofinnova in multiple companies: Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND), and Trius Therapeutics (TSRX-acquired by Cubist). Earlier in her career, she worked as an associate and principal investing in seed and early stage biotech at T2C2/Bio and Ventures West. Fierce Pharma named Maha one of 2023’s Fiercest Women in Life Sciences. Maha serves as an advisor to amplifyHERscience, a Yale Ventures initiative.